Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?

Despite the existence of effective medicines, heart failure continues to be the largest cause of illness and death worldwide. As a prospective family of drugs with potential cardiovascular advantages in non-diabetic patients, sodium-glucose co-transporter 2 inhibitors (SGLT2-I) have recently come to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehsan, Paghunda, Aburumman, Rawia N, Muthanna, Shivani Ishwarya, Menon, Swathi Radhakrishnan, Vithani, Vruti, Sutariya, Bansi, Montenegro, Diana M, Chukwu, Michael, Penumetcha, Sai Sri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780697/
https://www.ncbi.nlm.nih.gov/pubmed/36579255
http://dx.doi.org/10.7759/cureus.31777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780697/
https://www.ncbi.nlm.nih.gov/pubmed/36579255
http://dx.doi.org/10.7759/cureus.31777

Ejemplares similares